OPUS GENETICS INC. -
1.1000
25-November-24 16:45:01
15 minutes delayed
Stocks
+0.0900
+8.91%
Today's range
1.0200 - 1.1200
ISIN
N/A
Source
NASDAQ
-
05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Jan 2024 16:10:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
30 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 Nov 2023 16:38:14 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
27 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
13 Nov 2023 08:00:01 By Nasdaq GlobeNewswire
-
02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 16:52:46 By Nasdaq GlobeNewswire
-
01 Nov 2023 08:05:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
26 Oct 2023 08:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
06 Oct 2023 08:00:00 By Nasdaq GlobeNewswire
-
27 Sep 2023 08:00:12 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
11 Sep 2023 09:41:55 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
07 Sep 2023 09:00:00 By Nasdaq GlobeNewswire
-
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
28 Aug 2023 08:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
11 Aug 2023 08:00:00 By Nasdaq GlobeNewswire
-
08 Aug 2023 08:00:01 By Nasdaq GlobeNewswire
-
26 Jul 2023 08:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2023 17:19:14 By Nasdaq GlobeNewswire